BIOPHARMA
ByCan AbbVie’s 2025 Launches and Portfolio Expansion Offset Post-Humira Transition and Drive Sustainable Growth Beyond 2026?
Global | January 2026 — AbbVie Inc. accelerated its post-Humira transformation in 2025, advancing a diversified portfolio across…
Can Merck’s 2025 Launches, Label Expansions, and Oncology Leadership Sustain Growth Momentum Into 2026 and Beyond?
Global | January 2026 — Merck & Co., Inc. (MSD outside the U.S. and Canada) reinforced its position…
Can Eli Lilly’s 2025 Brand Launches and Label Expansions Redefine Leadership in Metabolic, Oncology, and Neuroscience Markets Beyond 2026?
Global | January 2026 — Eli Lilly and Company accelerated its transformation in 2025 through a series of…
Can Pfizer’s 2025 Brand Launches Across Vaccines, Oncology, and Specialty Care Reshape Its Growth Trajectory Beyond 2026?
Global | January 2026 — Pfizer Inc. advanced its post-pandemic transformation in 2025 through a series of targeted…
Is the U.S. Reopening the Door to Coverage Losses? ACA Subsidy Expiration Fuels Cost and Enrollment Uncertainty
23 January 2026 Executive Summary The expiration of enhanced Affordable Care Act (ACA) subsidies is continuing to drive…
Does the U.S. Exit from WHO Redefine Global Health Governance? Washington Completes Historic Withdrawal
23 January 2026 Executive Summary The United States has formally completed its withdrawal from the World Health Organization…
